Br J Cancer: Body Mass Index (BMI) and Absolute Lymphocyte Count (ALC): Predictors of disease-free survival for breast cancer patients
"Healthy China·Breast Cancer Critical Decade Action" was officially launched to help breast cancer survive...
The clinical trial application of BPI-16350 drug combination treatment of breast cancer by Betta Pharmaceuticals has been accepted
Pfizer and Celcuity have reached a partnership to develop PI3K for breast cancer...
The 2021 National Breast Cancer Conference and CSCO Breast Cancer Annual Conference held multiple guidelines...
Bioelectricity: Electromagnetic fields can affect the spread of breast cancer cells
Drug Research: Does GLP-1RA increase the risk of breast cancer?
JAMA Sub-Journal: These advanced breast cancers are expected to be cured!
Pfizer announces data on Ibrance's first-line treatment of HR+/HER2-metastatic breast cancer
When will triple-negative breast cancer produce landmark treatments?
Dialogue with Professor Ma Fei: In the new era of chemotherapy, patients with advanced breast
2021 CSCO Breast Cancer Guidelines: Interpretation of the updated key points of HER2+ neoadjuvant treatment for early breast cancer | 2021 CSCO BC
Prof. Yingying Xu: From population selection to plan formulation, "re-understanding" of neoadjuvant treatment for breast cancer | 2021 CSCO BC
Professor Wang Ting: Come from behind, different CDK4/6 inhibitors will benefit more Chinese breast cancer patients
-negative breast cancer and ovarian cancer has repeatedly failed
guidelines-HER2-positive early breast cancer neoadjuvant treatment
Molecular Cancer | Soochow University Zhang Lifeng/Chen Yan discovered the key role of circular RNA in triple-negative breast cancer
After breast cancer surgery, why did she have hot flashes, sweating, body aches and restlessness?
; biomarkers can effectively predict the prognosis of HR+/HER2+ breast cancer neoadjuvant therapy|Tumor News
Professor Ning Liao: Summary of key clinical studies on HER2-positive breast cancer